Vocalis Health COVID-19 Screening Tool Is Successfully Validated in Large Clinical Study

Vocalis Health notes the study included over 2,000 participants who spoke numerous languages including English, Hindi, Marathi, and Gujarati.

Results from an unblinded validation set of 288 participants demonstrated an AUC of 0.88, which translated to accuracy of 81.2 percent, sensitivity of 80.3 percent and specificity of 81.4 percent.

In addition to the results of this study, Vocalis Health today announced that its COVID-19 screening tool, VocalisCheck, has obtained a CE mark.  VocalisCheck is the first device with CE mark approval for its medical intended use of screening for COVID-19.

“PCR testing is being used to screen for COVID-19, which is an extremely expensive, resource-intensive, and time-consuming approach,” said Dr. Shady Hassan, Co-Founder, Chief Operating and Medical Officer of Vocalis Health. “Instead of misusing PCR testing for screening, utilizing a highly scalable screening tool like VocalisCheck can fill a significant gap in the current approach to COVID screening, with the ability to effectively funnel those with a high risk of infection to the appropriate diagnostic test.”

VocalisCheck has now proven its reliability to effectively identify COVID-19 risk in multiple studies, including this study in India, delivering reliable risk assessment for COVID-19 infection even in people who are not symptomatic.  In the study in India, a symptom checker alone correctly identified approximately 66 percent of the people with COVID-19 infection, while Vocalis Health’s COVID-19 vocal biomarker achieved >80 percent accuracy in assessing a person’s risk of COVID-19 infection.

“We are encouraged by the study’s findings, which further validate VocalisCheck’s ability to screen for COVID-19,” explained Tal Wenderow, CEO of Vocalis Health.  “These new results, combined with our recent CE-mark approval, demonstrate our commercial readiness to deploy the VocalisCheck screening tool to help businesses, governments, universities and others safely return to work, school, healthcare, and leisure while lightening the burden on health systems.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version